Resolution of Expert Panel for the Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria

DOI:

https://doi.org/10.21320/
Resolution of Expert Panel for the Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria  
  1. Кулагин А.Д., Лисуков И.А., Птушкин В.В. и др. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии. Онкогематология. 2014;9(2):20–8. doi: 10.17650/1818-8346-2014-9-2-20-28.
  2. [Kulagin AD, Lisukov IA, Ptushkin VV, et al. National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria. Oncohematology. 2014;9(2):20–8. doi: 10.17650/1818-8346-2014-9-2-20-28. (In Russ)]
  3. Kulagin A, Klimova O, Rudakova T, et al. Benefits and limitations of long-term eculizumab treatment for paroxysmal nocturnal hemoglobinuria (PNH): Real-world data from large cohort study in Russia. Blood (ASH Annual Meeting Abstracts). 2018;132:2589; doi: 10.1182/blood-2018-99-120139.
  4. Risitano А, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Sem Immunol. 2016;28(3):223–40. doi:10.1016/j.smim.2016.05.001.
  5. Brodsky R. Eculizumab: another breakthrough. Blood. 2017;129(8):922–3. doi: 10.1182/blood-2017-01-760496.
  6. De Fontbrune F, De Latour R. Ten years of clinical experience with eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria. Sem Hematol. 2018;55(3):124–9. doi:10.1053/j.seminhematol.2018.04.001.

License

Copyright (c) 2019 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.
2019-2

Downloads

Published

01.04.2019

Issue

Vol. 12 No. 2 (2019)
NEWS

How to Cite

Resolution of Expert Panel for the Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria. Clinical Oncohematology. 2019;12(2):240–242. doi:10.21320/.